Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and... 1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma

Loading next page...
 
/lp/wiley/combinations-of-single-nucleotide-polymorphisms-wwox-rs13338697-Mg1QP10oLB
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12745
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C,

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial